Full Press Release Details
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement
COPENHAGEN, Denmark; February 22, 2023 - Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons.
The company's managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company's managerial employees and their closely associated persons.
This company announcement includes the remaining part of the vesting and net settlement of the restricted stock units granted to Jan van de Winkel on December 5, 2019.
Please find below a statement of such trading in shares issued by Genmab A/S.
| 1. | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Jan G. J. van de Winkel | |
| 2. | Reason for the notification | ||
| a) | Position/status | President & Chief Executive Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Genmab A/S | |
| b) | LEI-code | 529900MTJPDPE4MHJ122 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code | Share DK0010272202 | |
| b) | Nature of the transaction | Acquisition due to vesting of restricted stock units | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| DKK 0.00 | 1,563 | ||
| d) | Aggregated information - Aggregated volume - Price | ||
| e) | Date of the transaction | 2023-02-22 | |
| f) | Place of the transaction | Outside a market place |
| Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 7 |
| Kalvebod Brygge 43 | Fax: +45 7020 2729 | Page 1/2 |
| 21560 Copenhagen V, Denmark | www.genmab.com | CVR no. 2102 3884 |
| LEI Code 529900MTJPDPE4MHJ122 |
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO) antibody medicines.
Marisol Peron, Senior Vice President, Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
The Company Announcement contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab ; the Y-shaped Genmab logo ; Genmab in combination with the Y-shaped Genmab logo ; HuMax ; DuoBody ; DuoBody in combination with the DuoBody logo ; HexaBody ; HexaBody in combination with the HexaBody logo ; DuoHexaBody and HexElect .
| Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 7 |
| Kalvebod Brygge 43 | Fax: +45 7020 2729 | Page 2/2 |
| 21560 Copenhagen V, Denmark | www.genmab.com | CVR no. 2102 3884 |
| LEI Code 529900MTJPDPE4MHJ122 |